KR102190981B1 - OspA의 돌연변이체 단편 및 이에 관련된 방법 및 용도 - Google Patents

OspA의 돌연변이체 단편 및 이에 관련된 방법 및 용도 Download PDF

Info

Publication number
KR102190981B1
KR102190981B1 KR1020157001969A KR20157001969A KR102190981B1 KR 102190981 B1 KR102190981 B1 KR 102190981B1 KR 1020157001969 A KR1020157001969 A KR 1020157001969A KR 20157001969 A KR20157001969 A KR 20157001969A KR 102190981 B1 KR102190981 B1 KR 102190981B1
Authority
KR
South Korea
Prior art keywords
ospa
disulfide bond
seq
bond type
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157001969A
Other languages
English (en)
Korean (ko)
Other versions
KR20150036191A (ko
Inventor
패어 콤스텟트
얼반 룬드버그
안드레아스 마인케
마르쿠스 한너
볼프강 쉴러
벤자민 와이젤
크리스토프 라이니쉬
브리기테 그로만
로버트 쉬레글
Original Assignee
발네바 오스트리아 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 발네바 오스트리아 게엠베하 filed Critical 발네바 오스트리아 게엠베하
Priority to KR1020207035357A priority Critical patent/KR102393038B1/ko
Publication of KR20150036191A publication Critical patent/KR20150036191A/ko
Application granted granted Critical
Publication of KR102190981B1 publication Critical patent/KR102190981B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020157001969A 2012-07-06 2013-07-08 OspA의 돌연변이체 단편 및 이에 관련된 방법 및 용도 Active KR102190981B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207035357A KR102393038B1 (ko) 2012-07-06 2013-07-08 OspA의 돌연변이체 단편 및 이에 관련된 방법 및 용도

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261668627P 2012-07-06 2012-07-06
US61/668,627 2012-07-06
US13/802,991 2013-03-14
US13/802,991 US8986704B2 (en) 2012-07-06 2013-03-14 Mutant fragments of OspA and methods and uses relating thereto
PCT/EP2013/064403 WO2014006226A1 (en) 2012-07-06 2013-07-08 MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207035357A Division KR102393038B1 (ko) 2012-07-06 2013-07-08 OspA의 돌연변이체 단편 및 이에 관련된 방법 및 용도

Publications (2)

Publication Number Publication Date
KR20150036191A KR20150036191A (ko) 2015-04-07
KR102190981B1 true KR102190981B1 (ko) 2020-12-15

Family

ID=49878705

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157001969A Active KR102190981B1 (ko) 2012-07-06 2013-07-08 OspA의 돌연변이체 단편 및 이에 관련된 방법 및 용도
KR1020207035357A Active KR102393038B1 (ko) 2012-07-06 2013-07-08 OspA의 돌연변이체 단편 및 이에 관련된 방법 및 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207035357A Active KR102393038B1 (ko) 2012-07-06 2013-07-08 OspA의 돌연변이체 단편 및 이에 관련된 방법 및 용도

Country Status (24)

Country Link
US (9) US8986704B2 (enExample)
EP (3) EP2869839B1 (enExample)
JP (1) JP6276258B2 (enExample)
KR (2) KR102190981B1 (enExample)
CN (2) CN104487084B (enExample)
AU (2) AU2013285364B2 (enExample)
CA (1) CA2876541C (enExample)
CY (1) CY1120772T1 (enExample)
DK (1) DK2869839T3 (enExample)
EA (2) EA201991059A1 (enExample)
ES (2) ES2688883T3 (enExample)
HR (1) HRP20181689T1 (enExample)
HU (1) HUE041286T2 (enExample)
LT (1) LT2869839T (enExample)
MX (2) MX364623B (enExample)
NZ (2) NZ733026A (enExample)
PL (1) PL2869839T3 (enExample)
PT (1) PT2869839T (enExample)
RS (1) RS57847B1 (enExample)
SI (1) SI2869839T1 (enExample)
SM (1) SMT201800557T1 (enExample)
TR (1) TR201815419T4 (enExample)
WO (1) WO2014006226A1 (enExample)
ZA (1) ZA201409222B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
HRP20191086T1 (hr) * 2014-01-09 2019-11-01 Valneva Austria Gmbh Mutantni ospa fragmenti i postupci i uporabe koji se na njih odnose
AU2015281021B9 (en) * 2014-06-27 2019-03-28 Ube Corporation Salt of halogen-substituted heterocyclic compound
WO2016022958A2 (en) * 2014-08-07 2016-02-11 The Trustees Of Columbia University In The City Of New York Tick-associated virus sequences and uses thereof
EP3393481A1 (en) * 2015-12-23 2018-10-31 Novartis Ag Oil-in-water emulsions including retinoic acid
WO2017139715A1 (en) * 2016-02-11 2017-08-17 The Translational Genomics Research Institute Systems and methods for the detection of infectious diseases
US12018054B2 (en) 2017-04-13 2024-06-25 Valneva Austria Gmbh Multivalent OspA polypeptides and methods and uses relating thereto
KR20190001421U (ko) 2019-05-26 2019-06-13 이준형 노크형 내부 수납식 칫솔
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
CN111269919B (zh) * 2020-03-19 2021-07-13 四川农业大学 玉米基因ZmLIP2及其应用
WO2021205022A1 (en) 2020-04-09 2021-10-14 Valneva Austria Gmbh Improved methods of producing a lipidated protein
MX2022012647A (es) * 2020-04-09 2023-01-16 Valneva Austria Gmbh Composiciones que comprenden tres proteinas de fusion de ospa para uso medico.
WO2023034932A1 (en) * 2021-09-02 2023-03-09 Vaxcyte, Inc. Stabilization of adjuvanted vaccine compositions and their use
WO2025015042A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen
WO2025015077A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4810428B2 (ja) 2003-09-30 2011-11-09 セントカー・インコーポレーテツド ヒトｅｐｏ模倣ヒンジコアミメティボディ、組成物、方法および使用
JP2019070007A (ja) 2006-09-26 2019-05-09 インフェクティアス ディジーズ リサーチ インスティチュート 合成アジュバントを含むワクチン組成物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008625B2 (en) * 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
EP1311540B1 (en) 2000-08-18 2007-12-19 Research Foundation Of State University Of New York Altered ospa of borrelia burgdorferi
CN101516905A (zh) 2006-09-15 2009-08-26 英特塞尔股份公司 疏螺旋体属抗原
TWI376385B (en) 2007-12-07 2012-11-11 Nat Health Research Institutes Production of lipidated proteins in e. coli
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
US8420352B2 (en) 2009-08-27 2013-04-16 Synaptic Research, Llc Protein delivery system to generate pluripotent stem (iPS) cells or tissue specific cells
KR20180082633A (ko) 2010-05-14 2018-07-18 박스알타 인코퍼레이티드 Ｏｓｐａ 키메라 및 백신에서 그의 용도
EP3167899B1 (en) 2010-09-03 2021-03-24 Valneva Austria GmbH Isolated polypeptide of the toxin a and toxin b proteins of c.difficile and uses thereof
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
US9925257B2 (en) 2011-09-23 2018-03-27 Forsyth Dental Infirmary For Children Vaccine and therapeutic delivery system
DK3785730T3 (da) 2011-12-06 2024-05-06 Valneva Austria Gmbh Aluminiumforbindelser til anvendelse i terapeutiske produkter og vacciner
EP2788200B1 (en) 2011-12-06 2018-07-04 Mubea Carbo Tech GmbH Wheel made out of fiber reinforced material and procedure to make an according wheel
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
HRP20191086T1 (hr) 2014-01-09 2019-11-01 Valneva Austria Gmbh Mutantni ospa fragmenti i postupci i uporabe koji se na njih odnose
CZ2014320A3 (cs) 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
EP3387006A4 (en) 2015-12-10 2019-05-08 National Research Council of Canada LIPIDATED STREPTOCOCCUS PNEUMONIAE
US12018054B2 (en) 2017-04-13 2024-06-25 Valneva Austria Gmbh Multivalent OspA polypeptides and methods and uses relating thereto
WO2019092002A1 (en) 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
EP3972639A1 (en) 2019-05-20 2022-03-30 Valneva SE A subunit vaccine for treatment or prevention of a respiratory tract infection
US10787501B1 (en) 2020-04-02 2020-09-29 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
WO2021205022A1 (en) 2020-04-09 2021-10-14 Valneva Austria Gmbh Improved methods of producing a lipidated protein
MX2022012647A (es) 2020-04-09 2023-01-16 Valneva Austria Gmbh Composiciones que comprenden tres proteinas de fusion de ospa para uso medico.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4810428B2 (ja) 2003-09-30 2011-11-09 セントカー・インコーポレーテツド ヒトｅｐｏ模倣ヒンジコアミメティボディ、組成物、方法および使用
JP2019070007A (ja) 2006-09-26 2019-05-09 インフェクティアス ディジーズ リサーチ インスティチュート 合成アジュバントを含むワクチン組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
INFECTION AND IMMUNITY, (2001), Vol.69, 4799~4807 1부.*
JOURNAL OF MOLECULAR BIOLOGY, (2005), Vol.350, 290~299 1부.*

Also Published As

Publication number Publication date
US9926343B2 (en) 2018-03-27
CN107602676B (zh) 2021-06-04
HK1209370A1 (en) 2016-04-01
EA201991059A1 (ru) 2020-01-31
EP3360568A1 (en) 2018-08-15
CY1120772T1 (el) 2019-12-11
US20170107263A1 (en) 2017-04-20
HK1257893A1 (en) 2019-11-01
EP3689372A1 (en) 2020-08-05
US11466058B2 (en) 2022-10-11
US20220185851A1 (en) 2022-06-16
KR102393038B1 (ko) 2022-04-29
US20140010835A1 (en) 2014-01-09
AU2013285364A1 (en) 2015-01-29
DK2869839T3 (en) 2018-10-15
EA033007B1 (ru) 2019-08-30
CN104487084B (zh) 2017-09-22
HRP20181689T1 (hr) 2018-12-28
US12195501B2 (en) 2025-01-14
EA201590162A1 (ru) 2015-06-30
MX391136B (es) 2025-03-21
PL2869839T3 (pl) 2018-12-31
AU2017218974C1 (en) 2020-02-20
US20170101446A1 (en) 2017-04-13
US8986704B2 (en) 2015-03-24
SMT201800557T1 (it) 2018-11-09
ES2688883T3 (es) 2018-11-07
AU2017218974A1 (en) 2017-09-07
CA2876541A1 (en) 2014-01-09
CN104487084A (zh) 2015-04-01
HK1207982A1 (en) 2016-02-19
JP2015522270A (ja) 2015-08-06
US20150250865A1 (en) 2015-09-10
SI2869839T1 (sl) 2018-11-30
CA2876541C (en) 2022-03-01
TR201815419T4 (tr) 2018-11-21
KR20200141096A (ko) 2020-12-17
US20150232517A1 (en) 2015-08-20
EP2869839A1 (en) 2015-05-13
RS57847B1 (sr) 2018-12-31
EP3360568B1 (en) 2020-03-04
ZA201409222B (en) 2016-08-31
US20230295245A1 (en) 2023-09-21
EP2869839B1 (en) 2018-09-05
KR20150036191A (ko) 2015-04-07
AU2017218974B2 (en) 2019-05-30
HK1248244A1 (zh) 2018-10-12
US10544194B2 (en) 2020-01-28
AU2013285364B2 (en) 2017-06-15
MX2015000013A (es) 2015-06-04
US20200239525A1 (en) 2020-07-30
US11208439B2 (en) 2021-12-28
ES2800873T3 (es) 2021-01-04
PT2869839T (pt) 2018-11-12
MX364623B (es) 2019-05-03
JP6276258B2 (ja) 2018-02-07
CN107602676A (zh) 2018-01-19
NZ703597A (en) 2017-06-30
US20180327460A1 (en) 2018-11-15
NZ733026A (en) 2019-09-27
HUE041286T2 (hu) 2019-05-28
WO2014006226A1 (en) 2014-01-09
LT2869839T (lt) 2018-11-12

Similar Documents

Publication Publication Date Title
US20230295245A1 (en) Mutant fragments of ospa and methods and uses relating thereto
HK40035688A (en) Mutant fragments of ospa and methods and uses relating thereto
HK1257893B (en) Mutant fragments of ospa and methods and uses relating thereto
HK1209370B (en) Mutant fragments of ospa and methods and uses relating thereto
HK1207982B (en) Mutant fragments of ospa and methods and uses relating thereto
EA046886B1 (ru) МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ
HK1248244B (zh) Ospa的突变片段以及其相关方法和用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150123

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180628

Comment text: Request for Examination of Application

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190927

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200526

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190927

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20200526

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200128

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180702

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180628

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20200916

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20200824

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200526

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20200128

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20180702

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20180628

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20201208

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20201208

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20201209

End annual number: 3

Start annual number: 1

PG1601 Publication of registration